Published in FDA Law Weekly, May 26th, 2005
Revenue for the first quarter ended March 31, 2005, was $12.7 million compared to $3.2 million for the same period in 2004. In March 2005, Dynavax and UCB Farchim (UCB) ended their allergy collaboration and Dynavax regained full rights to its allergy program.
Collaboration revenue for the first quarter 2005 reflects the ending of the UCB agreement and associated contractual terms. Included in first quarter 2005 collaboration revenue was a one-time noncash amount of $7 million resulting from the accelerated recognition of an upfront payment the company received...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.